MedTrace Logo

Monoclonal Antibody Therapy in Treating Patients With Brain Metastases

NCT00002751 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2013-06-20

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have brain metastases.

Conditions

Interventions

BIOLOGICAL

monoclonal antibody Me1-14 F(ab')2

Sponsors & Collaborators

Principal Investigators

  • Darell D. Bigner, MD, PhD · Duke University

Study Design

Purpose
TREATMENT

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1989-07-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002751 on ClinicalTrials.gov